Section edited by Christian Capitini, MD
Reaction to and/or perspectives on significant events in the field in the basic science area. May address a critical challenge, elaborate or extend a conversation of a focal article, provide an application of a theoretical perspective, or shed light on a particular issue in the field.
Commentary
Recent single institution clinical trial successes with anti-CD19 Chimeric Antigen Receptor (CAR) T cell therapy for B cell malignancies attracted significant attention from industry. Our center sought to rapi...
Journal for ImmunoTherapy of Cancer 2017 5:59
Published on: 18 July 2017
Commentary
Immune checkpoint inhibitors have emerged as a promising therapeutic option for metastatic cancers. However, they have been associated with inflammatory adverse reactions in various organ systems. A recent art...
Journal for ImmunoTherapy of Cancer 2017 5:24
Published on: 21 March 2017
Commentary
Mechanisms of innate and adaptive resistance to checkpoint blockade immunotherapy are under intense investigation with a view to broadening the therapeutic potential of this form of treatment. In a recent manu...
Journal for ImmunoTherapy of Cancer 2017 5:10
Published on: 21 February 2017
Commentary
Immunotherapy has had remarkable success in the treatment of some cancer types. However, pancreatic cancer has remained largely refractory to immunotherapy, including immune checkpoint inhibitors. Recently, Ji...
Journal for ImmunoTherapy of Cancer 2017 5:17
Published on: 21 February 2017
Commentary
A recent study by Eil at al. published in Nature in September 2016 provides evidence that alterations of the K+ homeostasis of tumor infiltrating lymphocytes (TILs) in necrotic areas of the tumor microenvironment...
Journal for ImmunoTherapy of Cancer 2017 5:2
Published on: 17 January 2017
Commentary
Harnessing the immune system to attack tumor cells by targeting tumor-associated or –preferably– tumor-specific antigens has emerged as a promising but challenging treatment option for malignant lymphomas. Fol...
Journal for ImmunoTherapy of Cancer 2017 5:6
Published on: 17 January 2017
Commentary
Inbred mice are the mainstay for preclinical cancer assessment of potential therapeutics, especially immune-based approaches. However, the use of young, lean, inbred mice housed under specific-pathogen-free co...
Journal for ImmunoTherapy of Cancer 2016 4:88
Published on: 20 December 2016
Commentary
Journal for ImmunoTherapy of Cancer 2016 4:87
Published on: 20 December 2016
Commentary
To date, the American Joint Committee on Cancer (AJCC) and the Union for International Cancer Control (UICC) tumor, nodes, metastasis (TNM) classification represents the standard system for evaluation of progn...
Journal for ImmunoTherapy of Cancer 2016 4:71
Published on: 15 November 2016
Commentary
Journal for ImmunoTherapy of Cancer 2016 4:54
Published on: 20 September 2016
Commentary
Journal for ImmunoTherapy of Cancer 2016 4:43
Published on: 16 August 2016
Commentary
Immune checkpoint blockade therapies are revolutionizing standard cancer treatments. Immune checkpoint inhibitors likely function to enhance the tumor specific antigen response in order to achieve favorable cl...
Journal for ImmunoTherapy of Cancer 2016 4:46
Published on: 16 August 2016
Commentary
Journal for ImmunoTherapy of Cancer 2016 4:42
Published on: 19 July 2016
Commentary
The recent use of T cell-based cancer immunotherapies, such as adoptive T-cell transfer and checkpoint blockade, yields increasing clinical benefit to patients with different cancer types. However, decrease of...
Journal for ImmunoTherapy of Cancer 2016 4:39
Published on: 19 July 2016
Commentary
The recent study by Hodi et al. published in the Journal of Clinical Oncology has evaluated unconventional response patterns during PD-1 inhibitor therapy using immune-related response criteria (irRC) in compa...
Journal for ImmunoTherapy of Cancer 2016 4:30
Published on: 21 June 2016
Commentary
Mounting an immune response sufficient to eradicate a tumor is the goal of modern immunotherapy. Single agent therapies with checkpoint inhibitors or costimulatory molecule agonists are effective only for a sm...
Journal for ImmunoTherapy of Cancer 2016 4:31
Published on: 21 June 2016
Commentary
The Common Rule is a set of ethical principles that provide guidance on the management of human subjects taking part in biomedical and behavioral research in the United States. The elements of the Common Rule ...
Journal for ImmunoTherapy of Cancer 2016 4:37
Published on: 21 June 2016
Commentary
The abscopal effect of radiation describes tumor regression in metastases outside of the field upon treatment of one site, and is mediated by radiation-induced anti-tumor T cells. The ability of radiation to g...
Journal for ImmunoTherapy of Cancer 2016 4:29
Published on: 17 May 2016
Commentary
Attention has recently focused on new cancer immunotherapy protocols aiming to activate T cell mediated anti-tumor responses. To this end, administration of antibodies that target inhibitory molecules regulati...
Journal for ImmunoTherapy of Cancer 2016 4:23
Published on: 19 April 2016
Commentary
Advances in cancer immunotherapy are leading to its increasing and successful application for the treatment of solid–tissue cancers. Despite the recent advances there are still significant barriers, in particu...
Journal for ImmunoTherapy of Cancer 2016 4:19
Published on: 19 April 2016
